Cancer Research
Hematology Malignancy Innovations in Clinical Trials
Current Issue:
May 2017
Past Issues:
October 2016
August 2015
- JAN1A14: VMP +/- Daratumumab for untreated myeloma patients.
- S1211: Elotuzumab and Bortezomib, Dexamethasone and Lenalidomide for newly diagnosed high-risk myeloma patients.
- CASE4A13: Ixazomib (MLN9708) plus Panobinostat and Dexamethasone for relapsed myeloma
- CASE1A09: Very low dose continuous azacytidine plus lenalidomide and dexamethasone for relapsed multiple myeloma.
- E3A06: Lenalidomide for patients with high-risk smoldering myeloma
- MLNM2A13: Ixazomib, lenalidomide and dexamethasone for newly diagnosed multiple myeloma
- MLNM1A15: Ixazomib maintenance after induction therapy for patients ineligible for autologous transplantation
December 2014
- MESO 1Z12: MSC Expanded Umbilical Cord Blood Transplant
- CTN 1101: Umbilical Cord Blood vs. Haploidentical Transplants
- BELL 1Z12: Haploidentical SCT with Genetically Modified T Cells to Stop GVHD
- UNMC 1413: Lenalidomide Maintenance After Autologous SCT
- CASE 9Z13: Targeted Marrow Irradiation in Reduced Intensity Stem Cell Transplant
- CCASE 12Z13: Allogeneic Transplant for Patients with Sickle Cell Anemia
- CASE 5913: Curcumin and Vitamin D for Patients with Early-Stage CLL Or SLL
- PRE 1413: Rituximab vs. Obinotuzumab for Patients with Low-Burden, Advanced-Stage Follicular Lymphoma
April 2014
- Treatment of High Risk Smoldering Myeloma
- BCL2 Inhibition for High Risk Relapsed CLL
- Lenalidomide plus R-CHOP for DLBCL
- Methoxyamine and Temozolomide in Patients with Advanced Solid Tumors
- Vaccine Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
- Treatment of Renal Tumors in Poor Surgical Candidates
December 2013
- Brentuximab Plus Bendamustine For Hodgkin Lymphoma In First Relapse
- Oral Azacytidine For Myeloid Malignancies
- Ex Vivo Umbilical Cord Blood Expansion With Human Mesenchymal Stem Cells (MSCs)
- Differentiation Therapy For Acute Myeloid Leukemia